Lantheus Holdings, Inc. (NASDAQ:LNTH - Get Free Report) saw unusually-high trading volume on Wednesday . Approximately 822,269 shares were traded during trading, a decline of 0% from the previous session's volume of 824,416 shares.The stock last traded at $92.92 and had previously closed at $80.05.
Analyst Ratings Changes
LNTH has been the topic of several research analyst reports. The Goldman Sachs Group initiated coverage on shares of Lantheus in a research report on Wednesday, December 18th. They set a "buy" rating and a $143.00 target price on the stock. StockNews.com downgraded shares of Lantheus from a "buy" rating to a "hold" rating in a research report on Thursday, November 21st. JMP Securities reaffirmed a "market outperform" rating and issued a $112.00 price objective on shares of Lantheus in a report on Tuesday, January 14th. Finally, Truist Financial upped their price objective on shares of Lantheus from $120.00 to $127.00 and gave the company a "buy" rating in a report on Thursday. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, Lantheus has a consensus rating of "Moderate Buy" and a consensus price target of $132.86.
View Our Latest Stock Analysis on LNTH
Lantheus Price Performance
The stock's fifty day moving average is $89.89 and its 200-day moving average is $96.73. The stock has a market cap of $6.52 billion, a PE ratio of 15.61 and a beta of 0.44.
Lantheus (NASDAQ:LNTH - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.57 by ($0.23). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The firm had revenue of $391.11 million during the quarter, compared to analysts' expectations of $376.61 million. On average, sell-side analysts expect that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.
Insiders Place Their Bets
In other Lantheus news, Director James H. Thrall sold 1,000 shares of the stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total transaction of $94,760.00. Following the completion of the transaction, the director now owns 33,207 shares of the company's stock, valued at $3,146,695.32. This trade represents a 2.92 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 1.50% of the stock is currently owned by insiders.
Institutional Inflows and Outflows
Several hedge funds have recently bought and sold shares of the stock. Janus Henderson Group PLC boosted its stake in Lantheus by 72.7% during the fourth quarter. Janus Henderson Group PLC now owns 6,198,689 shares of the medical equipment provider's stock worth $554,583,000 after buying an additional 2,610,118 shares during the period. Farallon Capital Management LLC boosted its stake in Lantheus by 79.9% during the fourth quarter. Farallon Capital Management LLC now owns 5,316,227 shares of the medical equipment provider's stock worth $475,590,000 after buying an additional 2,361,000 shares during the period. Geode Capital Management LLC lifted its position in shares of Lantheus by 2.0% during the third quarter. Geode Capital Management LLC now owns 1,683,500 shares of the medical equipment provider's stock worth $184,798,000 after purchasing an additional 32,551 shares in the last quarter. T. Rowe Price Investment Management Inc. lifted its position in shares of Lantheus by 40.5% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,509,332 shares of the medical equipment provider's stock worth $135,025,000 after purchasing an additional 435,445 shares in the last quarter. Finally, Reinhart Partners LLC. lifted its position in shares of Lantheus by 9.9% during the fourth quarter. Reinhart Partners LLC. now owns 1,366,873 shares of the medical equipment provider's stock worth $122,280,000 after purchasing an additional 123,282 shares in the last quarter. Hedge funds and other institutional investors own 99.06% of the company's stock.
About Lantheus
(
Get Free Report)
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.
Further Reading
Before you consider Lantheus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lantheus wasn't on the list.
While Lantheus currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
